XML 73 R64.htm IDEA: XBRL DOCUMENT v3.22.2.2
Commitments and Contingencies (Details) - Schedule of milestone payments - USD ($)
 6 Months Ended 12 Months Ended
Jun. 30, 2022
Dec. 31, 2021
Payment One [Member]    
Commitments and Contingencies (Details) - Schedule of milestone payments [Line Items]    
Milestone Filing of an Investigational New Drug (or any foreign equivalent) for a Licensed Product Filing of an Investigational New Drug (or any foreign equivalent) for a Licensed Product
Payment $ 50,000 $ 50,000
Payment Two [Member]    
Commitments and Contingencies (Details) - Schedule of milestone payments [Line Items]    
Milestone Dosing of first patient in a Phase 1 Clinical Trial of a Licensed Product Dosing of first patient in a Phase 1 Clinical Trial of a Licensed Product
Payment $ 100,000 $ 100,000
Payment Three [Member]    
Commitments and Contingencies (Details) - Schedule of milestone payments [Line Items]    
Milestone Dosing of first patient in a Phase 2 Clinical Trial of a Licensed Product Dosing of first patient in a Phase 2 Clinical Trial of a Licensed Product
Payment $ 250,000 $ 250,000
Payment Four [Member]    
Commitments and Contingencies (Details) - Schedule of milestone payments [Line Items]    
Milestone Receipt of New Drug Application (“NDA”) (or foreign equivalent) approval for a Licensed Product Receipt of New Drug Application (“NDA”) (or foreign equivalent) approval for a Licensed Product
Payment $ 500,000 $ 500,000
Payment Five [Member]    
Commitments and Contingencies (Details) - Schedule of milestone payments [Line Items]    
Milestone Achievement of First Commercial Sale of Licensed Product Achievement of First Commercial Sale of Licensed Product
Payment $ 1,000,000 $ 1,000,000